Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis

Table 1

Characteristics of 502 TNBC patients.

Factor		Rate (%)
Number of patients	502	100
Age at diagnosis (years)
Median	55
Mean	56
Range	24–98
Clinical staging (cTNM)
I	97	19.5
II	246	49
III	132	26
IV	27	5.5
Initial clinical tumor staging
cT0	7	1
cT1	111	22
cT2	248	49.5
cT3	58	12
cT4	76	15
No available data	2	0.5
Initial clinical node staging
cN0	243	48
cN1	180	36
cN2	58	11.5
cN3	19	4
No available data	2	0.5
HER2 expression
0 or 1+	431	86
2+, FISH negative	71	14
Histological type
NST	416	83
Lobular	25	5
Medullar	11	2
Apocrine	11	2
Metaplastic	20	4
Others	20	4
G
1	21	4
2	165	33
3	310	62
No available data	6	1
Ki-67 expression
<14%	140	28
14–30%	183	36.5
>30%	133	26.5
No available data	46	9
Vimentin expression assessed
Yes	443	88
No	59	12
Vimentin
Positive	71/443	16
Negative	372/443	84
Contralateral breast cancer	41	8
Other primary cancer (other than contralateral breast cancer)	45	9

FISH: fluorescence in situ hybridization.